[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) CEO and Director Joseph K. Belanoff reported insider stock sales on October 1, 2025 executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.

Sales were reported in three tranches of 5,616, 31,190, and 3,194 common shares at weighted average prices of $84.2895, $85.164, and $85.6662, respectively. The filing notes price ranges for each tranche and that detailed breakdowns are available from the issuer upon request.

Following these transactions, indirect holdings stood at 2,781,370 shares in the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which the reporting person has voting power and disclaims beneficial ownership except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELANOFF JOSEPH K

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		S(1)		5,616	D	$84.2895(2)	2,815,754	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Common Stock	10/01/2025		S(1)		31,190	D	$85.164(4)	2,784,564	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Common Stock	10/01/2025		S(1)		3,194	D	$85.6662(5)	2,781,370	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.58 to $84.53 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.5875 to $85.575 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.63 to $85.785 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff.	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CORT's CEO report on 10/01/2025?

Three common stock sales: 5,616 shares at $84.2895, 31,190 shares at $85.164, and 3,194 shares at $85.6662 (weighted averages).

Were the CORT CEO's sales under a Rule 10b5-1 plan?

Yes. The filing states the trades were made under a Rule 10b5-1 plan adopted on November 26, 2024.

How many CORT shares did the CEO hold after these transactions?

Indirect holdings were 2,781,370 shares after the reported sales.

What were the price ranges for each tranche of CORT stock sold?

Ranges disclosed: $83.58–$84.53, $84.5875–$85.575, and $85.63–$85.785 per share.

How are the CEO's CORT shares held?

Shares are held indirectly in the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02; voting power is noted and beneficial ownership is disclaimed except for pecuniary interest.

Did the filing report any derivative security transactions?

No. Table II shows no derivative securities acquired or disposed of.